Changes in Beneficial Ownership · 4
Glaukos Corporation
GKOSNYSEEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
form4-03192026_040303.xml
Filing details
- Report period
- 2026-03-16
- Issuer
- GLAUKOS Corp
- Issuer CIK
- 0001192448
- Trading symbol
- GKOS
Reporting owner 1
- Name
- Burns Thomas William
- Reporting owner CIK
- 0001644557
- Relationship
- Director · Officer
- Officer title
- CHAIRMAN & CEO
- Address
- C/O GLAUKOS CORPORATION, ONE GLAUKOS WAY, ALISO VIEJO, CA, 92656
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | 2026-03-16 | F · Form 4 | 2,801[F1] | D | 98.94 | 242,451[F2] | D |
Table key
- F · Form 4
- Securities delivered or withheld for exercise price or tax liability under Rule 16b-3
- D
- Direct
Non-derivative holdings
| Security | Amount owned | Ownership | Nature of ownership |
|---|---|---|---|
| Common Stock | 961,285 | I | Through the Burns Family Trust |
| Common Stock | 238,107 | I | Through the Burns Annuity Trust |
| Common Stock | 120,000 | I | Through the Burns Charitable Remainder Trust |
| Common Stock | 100,000 | I | Through the Thomas W. Burns Irrevocable Trust |
| Common Stock | 100,000 | I | Through the Janet M. Burns Irrevocable Trust |
Table key
- I
- Indirect
Footnotes
- F1
- Consists of shares withheld by the Issuer with respect to tax withholding obligations of the Reporting Person upon vesting and delivery of shares of common stock underlying restricted stock units previously granted by the Issuer on March 14, 2024.↩ 1
- F2
- Includes 64,610 restricted stock units that have not yet vested or been delivered to the Reporting Person.↩ 1
Signature 1
- Signed
- Diana Scherer, Attorney-in-Fact
- Date
- 2026-03-19
Company context
Glaukos (www.glaukos.com) is an ophthalmic pharmaceutical and medical technology company focused on developing and commercializing novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. Glaukos first developed Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to the traditional glaucoma treatment paradigm, launching its first MIGS device commercially in 2012. In 2024, Glaukos commenced commercial launch activities for iDose® TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical designed to deliver 24/7 glaucoma drug therapy inside the eye for extended periods of time. Glaukos also markets the only FDA-approved corneal cross-linking therapy utilizing a proprietary bio-activated pharmaceutical for the treatment of keratoconus, a rarely diagnosed corneal disorder. Glaukos continues to successfully develop and advance a robust pipeline of novel,